Neurological Institute Outcomes
Movement Disorders
Huntington Disease
Cleveland Clinic's Neurological Institute has been designated as a Huntington's Disease Society of America Center of Excellence.
Change in Depressive Symptoms in Huntington Disease (N = 68)
2022 – 2023
HD = Huntington Disease, PHQ-9 = Patient Health Questionnaire
Sixty-eight patients with Huntington disease (HD) completed the PHQ-9 at least twice in 2022-2023, with the first follow-up in 2022. The median duration of follow-up was 256.5 days (range, 221-295 days). Of those, 12 (17.7%) improved, 44 (64.7%) remained stable, and 12 (17.7%) worsened. A change of 5 points is considered clinically significant in patients whose initial PHQ-9 is ≥ 10.¹
Change in PROMIS® Global Health Ratings for Patients With Huntington Disease (N = 75)
2022 – 2023
HD = Huntington disease, PROMIS = Patient-Reported Outcomes Measurement Information System
The PROMIS-10 questionnaire is a self-reported measure of physical and emotional health status reflecting health-related quality of life. Seventy-five HD patients completed the PROMIS-10 at least twice in 2022-2023 and the second follow-up in 2023. The median duration of follow-up was 321 days (range, 69-552 days). A clinically meaningful change was defined as a total change of > 5 T-score points.² Of the 75 patients, 13 (17.3%) improved, 40 (53.3%) remained stable, and 22 (29.3%) worsened.
